Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 401 citing articles:

ACG Clinical Guideline: Management of Crohn's Disease in Adults
Gary R. Lichtenstein, Edward V. Loftus, Kim L. Isaacs, et al.
The American Journal of Gastroenterology (2018) Vol. 113, Iss. 4, pp. 481-517
Closed Access | Times Cited: 1143
Ulcerative colitis
Taku Kobayashi, Britta Siegmund, Catherine Le Berre, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Closed Access | Times Cited: 1052
Pathophysiology of Inflammatory Bowel Diseases
John T. Chang
New England Journal of Medicine (2020) Vol. 383, Iss. 27, pp. 2652-2664
Closed Access | Times Cited: 857
Crohn’s disease
Giulia Roda, Siew C. Ng, Paulo Gustavo Kotze, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Closed Access | Times Cited: 711
Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
Matthias Friedrich, Mathilde Pohin, Fiona Powrie
Immunity (2019) Vol. 50, Iss. 4, pp. 992-1006
Open Access | Times Cited: 591
Targeting immune cell circuits and trafficking in inflammatory bowel disease
Markus F. Neurath
Nature Immunology (2019) Vol. 20, Iss. 8, pp. 970-979
Open Access | Times Cited: 521
Drug development in the era of precision medicine
Sarah A. Dugger, Adam Platt, David B. Goldstein
Nature Reviews Drug Discovery (2017) Vol. 17, Iss. 3, pp. 183-196
Open Access | Times Cited: 411
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck, et al.
The Lancet (2021) Vol. 397, Iss. 10275, pp. 754-766
Closed Access | Times Cited: 407
Treatment of Inflammatory Bowel Disease: A Comprehensive Review
Zhaobei Cai, Shu Wang, Jiannan Li
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 407
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Alexander R. Moschen, Herbert Tilg, Tim Raine
Nature Reviews Gastroenterology & Hepatology (2018) Vol. 16, Iss. 3, pp. 185-196
Closed Access | Times Cited: 393
The Immunobiology of the Interleukin-12 Family: Room for Discovery
Elia D. Tait Wojno, Christopher A. Hunter, Jason S. Stumhofer
Immunity (2019) Vol. 50, Iss. 4, pp. 851-870
Open Access | Times Cited: 378
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei, et al.
Annals of the Rheumatic Diseases (2018) Vol. 77, Iss. 9, pp. 1295-1302
Open Access | Times Cited: 324
Psoriasis: Which therapy for which patient
Shivani B. Kaushik, Mark Lebwohl
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 1, pp. 27-40
Closed Access | Times Cited: 320
15 years of GWAS discovery: Realizing the promise
Abdel Abdellaoui, Loïc Yengo, Karin J. H. Verweij, et al.
The American Journal of Human Genetics (2023) Vol. 110, Iss. 2, pp. 179-194
Open Access | Times Cited: 292
Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
Lars Fugger, Lise T. Jensen, Jamie Rossjohn
Cell (2020) Vol. 181, Iss. 1, pp. 63-80
Closed Access | Times Cited: 272
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
Geert R. DʼHaens, Remo Panaccione, Filip Baert, et al.
The Lancet (2022) Vol. 399, Iss. 10340, pp. 2015-2030
Closed Access | Times Cited: 257
Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
Georg Schett, Iain B. McInnes, Markus F. Neurath
New England Journal of Medicine (2021) Vol. 385, Iss. 7, pp. 628-639
Open Access | Times Cited: 240
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Daniel C. Baumgart, Catherine Le Berre
New England Journal of Medicine (2021) Vol. 385, Iss. 14, pp. 1302-1315
Closed Access | Times Cited: 239
Effector T Helper Cell Subsets in Inflammatory Bowel Diseases
Tanbeena Imam, Sungtae Park, Mark H. Kaplan, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 231
Advancing the use of genome-wide association studies for drug repurposing
William R. Reay, Murray J. Cairns
Nature Reviews Genetics (2021) Vol. 22, Iss. 10, pp. 658-671
Closed Access | Times Cited: 211
Pyoderma gangrenosum
Emanual Maverakis, Angelo Valerio Marzano, Stephanie T. Le, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 203
Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease
H Schmitt, Ulrike Billmeier, Walburga Dieterich, et al.
Gut (2018) Vol. 68, Iss. 5, pp. 814-828
Open Access | Times Cited: 201
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis
Siddharth Singh, M. Hassan Murad, Mathurin Fuméry, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 12, pp. 1002-1014
Open Access | Times Cited: 199
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
William J. Sandborn, Marc Ferrante, Bal Raj Bhandari, et al.
Gastroenterology (2019) Vol. 158, Iss. 3, pp. 537-549.e10
Open Access | Times Cited: 183
IL-23 in inflammatory bowel diseases and colon cancer
Markus F. Neurath
Cytokine & Growth Factor Reviews (2018) Vol. 45, pp. 1-8
Closed Access | Times Cited: 179
Page 1 - Next Page

Scroll to top